Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients.
Interferon (IFN) demonstrates antiviral activity by binding to receptors on the cell surface. Expression of the IFN receptor in hepatocytes may be directly associated with a hepatitis C virus (HCV) infection and the response to IFN therapy. A competitive PCR method was developed to measure IFN alpha/beta (alphabeta) receptor mRNA in liver samples obtained by needle biopsy. Thirty-one patients with chronic hepatitis C (21 without cirrhosis, 10 with cirrhosis) and six normal subjects were used. Eighteen of the 21 patients without cirrhosis received the IFN therapy. Competitive PCR was carried out using IFN alphabeta receptor gene-specific primers and a specific competitor. Expression of the receptor was detected in all liver samples. There was no association between the expression level and serum alanine aminotransferase level, serum (2'-5') oligo (A) synthetase level, amount of serum HCV RNA, or HCV genotype. The expression level in patients with chronic hepatitis was significantly higher than that in normal livers (P < 0.05) and in cirrhotic livers (P< 0.01). Seven of the 18 patients treated with IFN demonstrated a sustained response to IFN (sustained responders), and the remaining 11 did not (nonsustained responders). The expression level of IFN alphabeta receptor mRNA in the sustained responders was significantly higher than that in the nonsustained responders (P< 0.01). Thus, the expression of IFN alphabeta receptor mRNA may be one of the host factors influencing the response to IFN therapy.
First Department of Internal Medicine, Kanazawa University School of Medicine, Ishikawa, Japan.
E
E
Mizukoshi
S
S
Kaneko
M
M
Yanagi
H
H
Ohno
K
K
Kaji
S
S
Terasaki
A
A
Shimoda
E
E
Matsushita
K
K
Kobayashi
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D015152:Blotting, Northern; D005260:Female; D015870:Gene Expression; D016174:Hepacivirus / Q000145:classification / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000276:immunology* / Q000473:pathology / Q000628:therapy / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D008099:Liver / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D012367:RNA, Viral / Q000097:blood; D053633:Receptor, Interferon alpha-beta; D017471:Receptors, Interferon / Q000032:analysis* / Q000235:genetics
D016898:Interferon-alpha; D008565:Membrane Proteins; D012333:RNA, Messenger; D012367:RNA, Viral; D017471:Receptors, Interferon; D053633:Receptor, Interferon alpha-beta; D016899:Interferon-beta; D000410:Alanine Transaminase